Business Context and Reporting Period
This Form 8-K reports on the Annual Meeting of Stockholders held by Ultragenyx Pharmaceutical Inc. on June 18, 2015. The meeting was conducted virtually via the Internet. The record date for the meeting was April 21, 2015, with 35,871,666 shares of common stock outstanding and entitled to vote.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance matters and voting results.
Material Changes and Voting Results
A total of 32,437,160 shares were voted in person or by proxy. The following proposals were approved:
- Proposal No. 1: Election of Directors
- Michael Narachi: 29,842,233 votes For; 643,501 votes Withheld; 1,951,426 Broker Non-Votes.
- Clay B. Siegall, Ph.D.: 29,835,203 votes For; 650,531 votes Withheld; 1,951,426 Broker Non-Votes.
- Both nominees were elected to the Board of Directors for a term ending at the 2018 Annual Meeting.
- Proposal No. 2: Ratification of Independent Registered Accounting Firm
- Stockholders ratified the selection of Ernst & Young LLP for the fiscal year ending December 31, 2015.
- Votes For: 32,410,116
- Votes Against: 3,646
- Abstentions: 23,398
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to the disclosure of voting results.
Key Facts for Investor Verification
- Verify the total number of shares outstanding (35,871,666) versus shares voted (32,437,160) to assess shareholder participation rates.
- Confirm the tenure of the newly elected Class II directors (Michael Narachi and Clay B. Siegall) through the 2018 Annual Meeting.
- Note the ratification of Ernst & Young LLP as the independent auditor for the 2015 fiscal year.
- Review the Definitive Proxy Statement on Schedule 14A filed on April 28, 2015, for detailed background on the proposals.